Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam
- PMID: 2850139
- DOI: 10.1159/000238586
Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam
Abstract
The beta-lactamase inhibitory properties of 6-acetylmethylene penicillanic acid (6-AMPA) were investigated and compared with those of other beta-lactamase inhibitors. 6-AMPA inhibited the TEM-1, TEM-2, SHV-1, PSE-1, PSE-2, PSE-3, PSE-4, OXA-2, OXA-3, and Staphylococcus aureus beta-lactamases. It also inhibited the chromosomally-mediated beta-lactamases of the Richmond-Sykes type Ia, Ic and Id type and the type IV Klebsiella enzymes. Beta-lactamases of Branhamella catarrhalis and Bacteroides fragilis were inhibited. The 6-AMPA I50 values for various enzymes were less than 0.01 microgram/ml TEM-1 and PSE-4, and 0.01 microgram/ml SHV-1, 0.02 microgram/ml S. aureus, 0.04 microgram/ml Proteus vulgaris, 0.04 microgram/ml K. oxytoca, 6.8 micrograms/ml P99, and 9.7 micrograms/ml Sabath-Abraham Pseudomonas enzyme. With isolated beta-lactamases 6-AMPA was a more potent inhibitor than clavulanate or sulbactam. 6-AMPA was an irreversible inhibitor of beta-lactamases. The penetration index for Escherichia coli JT4 was 23 compared to 3 for clavulanate. 6-AMPA at 10 micrograms/ml acted synergistically with ampicillin against beta-lactamase containing bacteria, but it was less active than clavulanate and did not act synergistically with ampicillin against Enterobacter, Citrobacter or Pseudomonas. Although 6-AMPA has excellent beta-lactamase inhibitory properties with isolated enzymes, it is less useful with intact organisms.
Similar articles
-
Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.Drugs Exp Clin Res. 1987;13(3):145-8. Drugs Exp Clin Res. 1987. PMID: 3040368
-
Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.Infection. 1991 Mar-Apr;19(2):106-9. doi: 10.1007/BF01645578. Infection. 1991. PMID: 1646771
-
Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.Antimicrob Agents Chemother. 1994 Apr;38(4):767-72. doi: 10.1128/AAC.38.4.767. Antimicrob Agents Chemother. 1994. PMID: 8031044 Free PMC article.
-
Evolution of beta-lactamase inhibitors.Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S727-32. doi: 10.1093/clinids/13.supplement_9.s727. Rev Infect Dis. 1991. PMID: 1656513 Review.
-
Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.Am J Med. 1985 Nov 29;79(5B):2-12. doi: 10.1016/0002-9343(85)90123-8. Am J Med. 1985. PMID: 3907341 Review.
Cited by
-
Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.Infection. 1995 Jul-Aug;23(4):191-200. doi: 10.1007/BF01781195. Infection. 1995. PMID: 8522374 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous